TL;DR: Conducted a full-stack product analysis of SastaSundar — one of India's earliest online pharmacy platforms — identifying three structural revenue leaks worth ₹80–120 Cr in recoverable GMV. Designed a phased solution across prescription upload optimization, cold-chain hardening, and B2B intelligence, backed by root cause analysis, RICE prioritization, a multi-layer metrics framework, and three compounding growth loops.
About SastaSundar
SastaSundar is a hybrid online pharmacy operating a B2C consumer app alongside a B2B distribution network serving 70,000+ retail pharmacy partners across East and Central India — West Bengal, Odisha, Bihar, Jharkhand, and Assam. Their brand promise — genuine medicines at lower prices — is a direct attack on the counterfeit medicine culture at local chemist shops.
The Indian online pharmacy market is valued at ~₹37,000 Cr ($4.5B USD) and growing at 18–22% CAGR, driven by smartphone penetration in Tier 2/3 cities and rising chronic disease burden. SastaSundar is uniquely positioned to capture this growth through its regional distribution infrastructure — but three structural platform problems are actively eroding both B2B retention and B2C conversion.
The Core Insight
SastaSundar's growth ceiling is not a demand problem — it is a trust and infrastructure problem. Customers want to buy medicines online. What stops them is friction at the prescription gate, fear of receiving a spoiled cold-chain medicine, and lack of confidence in whether the platform is genuinely regulated.
| Problem | Why It Matters | Revenue Risk | |
|---|---|---|---|
| P1 | Rx/OTC compliance tension creating UX friction | 35% of Rx upload attempts fail → direct conversion loss + compliance exposure | ~₹45–60 Cr annual revenue leak |
| P2 | Cold-chain medicine spoilage | 25–30% of Indian pharma SKUs require cold chain; returns destroy NPS and health trust | ~₹8–12 Cr annual waste + brand risk |
| P3 | Prescription upload success at 65% | Below the 85%+ industry benchmark; highest single point of Rx funnel abandonment | Every 1% gain ≈ ₹1.2–1.8 Cr incremental GMV |
Critical Interdependency: These three problems are not independent. A cold-chain SKU that also requires a prescription fails at two gates simultaneously. A compliance rule that is overly strict compounds P3. Solving them in isolation creates local optima; solving them as a system creates compounding value.
I mapped three distinct user types across the B2C and B2B surface.
Persona 1: Ramesh — The Chronic Patient (B2C)
Age 52, Patna. Buys metformin and insulin monthly for Type 2 diabetes. Mid-range Android, mobile internet. Monthly order value ₹1,200–1,800.
Core JTBD: "Get my regular medicines reliably, without having to physically visit a chemist or deal with a broken app experience."
Key friction points discovered through journey mapping: